Renal Denervation: A Revival or The Same Old Story

Travis Chong, Michael Nguyen

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite well-established pharmacological treatment, hypertension has remained a large contributor to noncommunicable deaths. Given the well-known association of hypertension with adverse cardiovascular disease the importance of blood pressure control has never been more crucial. Traditionally, pharmacological management has been the mainstay of care, however, with a growing burden of disease alternative and innovative approaches are now being considered. Minimally invasive catheter-based ablation systems, targeting renal sympathetic nerves, has been proposed as a more permanent way to control blood pressure. However, the clinical data supporting renal denervation has had many rises and falls throughout the years. With the promising results of the recent second-generation clinical trials there has been a renewed area of interest for renal denervation in the treatment of hypertension.

Original languageEnglish
Pages (from-to)843-847
JournalHeart Lung and Circulation
Volume30
Issue number6
DOIs
Publication statusPublished - Jun 2021

Fingerprint

Dive into the research topics of 'Renal Denervation: A Revival or The Same Old Story'. Together they form a unique fingerprint.

Cite this